دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 4,800,000 تومان- قیمت ویژه : 2,400,000تومان
پکیج دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
قیمت : 1,500,000 تومان- قیمت ویژه : 750,000تومان
Making prostate cancer screening fit for purpose
doi : 10.1016/S1470-2045(25)00672-2
Volume 26, Issue 12, December 2025, Page 1511
Defining eligibility for lung cancer screening based on individual risk
Adjuvant capecitabine in early-stage triple-negative breast cancer? Yes, but for whom?
Increased extent of neurosurgical resection in IDH-mutated glioma: issues for translation to standard practice
Focused ultrasound treatments could increase survival in individuals with glioma
Targeting IDH mutation: another milestone, but not the finish line
A deliverable national cancer control plan for the UK: lessons from abroad and the need for discipline at home
SunRISe-4 perioperative safety and TURBT stratification – Authors' reply
Misclassification of p16-positive, HPV-negative patients biases de-escalation trials
Misclassification of p16-positive, HPV-negative patients biases de-escalation trials – Authors' reply
New Zealand extends breast cancer screening to 70–74-year-olds
Europe's Beating Cancer Plan delayed by “legislative inaction�
More e-cigarette users than cigarette smokers for the first time in the UK
Government shutdown and Medicare changes impact cancer care in the USA
Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study
Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
Total neoadjuvant therapy followed by non-operative management or surgery in stage II–III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group
Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study
Neurocognitive outcomes in patients with brain metastases: a systematic review
SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials
The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus
